

Stans, 25th August 2009

Mondobiotech Holding AG goes public on 26th August 2009 at the SIX Swiss Exchange in Zürich under the SIX Symbol RARE

Letter from the Founders ¹

Founded by Vera, Michael, Fabio, and Patrick with Dorian – an expert in the fields of immunology, retrovirology and molecular genetics – the aim of Mondobiotech is to assist a community of patients that mainstream medical practice has overlooked and underserved: patients suffering from rare and neglected diseases. Helping this community is Mondobiotech's sole mission and priority.

Mondobiotech analyses peptides that are naturally occurring in the human body in order to identify promising candidates for the development of medicinal products for use in the treatment of rare and neglected diseases. The candidates in question are then licensed or sold to third parties. Thus far more than 300 such candidates have been discovered; seven have already been licensed to pharmaceutical and biotechnology companies.

More than just a company, Mondobiotech is a community of people dedicated to the search for treatments of rare and neglected diseases and to the support of sufferers from these diseases. The community in question is made up of biologists, biochemists, physicians, patients and patient advocacy organisations as well as other persons and organisations who share their experiences, know-how, expertise and skills.

Mondobiotech traces its origins back to 2000. Throughout the course of its subsequent growth we have sought to infuse it with an ethos of humanitarianism and service to society. In line with these ideals, Mondobiotech is now being listed on the SIX Swiss Exchange under the ticker symbol RARE.

The ticker symbol RARE stands for Mondobiotech's core ambition: to improve the lives of patients afflicted by rare and neglected diseases. We believe that people affected by or involved in rare diseases will benefit thanks to the public listing of Mondobiotech and have designed our listing to achieve this end.

Mondobiotech's philosophy is summed up by a single phrase:
to change the world by changing the world of medicine.

¹ Much of this was inspired by the letter of the founders of Google Inc. contained in the prospectus of Google Inc. for its initial public offering in 2004.

Corporate structure

A dual class share structure providing for common shares (Stammaktien) and shares with privileged voting rights (Stimmrechtsaktien) has been put in place by our existing shareholders. Only the common shares will be listed for the time being. This dual structure will make it harder for outside parties to take over or gain influence over Mondobiotech. It will also insure that the company's leadership has the ability to continue the innovative, long term approach that has characterised Mondobiotech from the outset.

Mondobiotech's board of directors consists in individuals who are recognized leaders in their fields. It includes: Prinz Michael von und zu Liechtenstein, who acts as chairman of the board and is an experienced entrepreneur with a long term commitment to Mondobiotech; Prof. Dr. Robert Huber, who in 1988 was awarded the Nobel Prize in Chemistry for the first structure determination of a membrane-bound protein; Prof. Dr. Thomas Cerny, Head of the Medical Oncology-Hematology Department of the Kantonsspital of St. Gallen, and president of the Swiss Cancer League; and Prof. Michael A. Keller, Stanford University's Chief Librarian, a world leader in the creation of innovative WWW-based publishing, research environments and digital libraries.

We believe that our expert management team's passionate commitment to the care and support of patients affected by rare and neglected diseases will insure Mondobiotech's continuing success.

Business

At the present time, Mondobiotech has licensed seven medicinal product candidates with NASDAQ-listed biotech companies (InterMune (ITMN); Biogen Idec MA (BIIB); United Therapeutics/LungRX (UTHR)).

More than 300 medicinal product candidates discovered by Mondobiotech researchers are currently in development. Six orphan medicinal product designations (OMPD) have already been received from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Future Funding

To continue its growth strategy and to fund further development of its medicinal product candidates, the company plans to increase its share capital through the issuance of new shares out of its existing authorized share capital on a continuous basis following the listing. The company intends to issue such new shares to existing shareholders, new investors and/or individuals and entities that are directly or indirectly affected by and/or involved in the treatment of rare and neglected diseases, such as patients, their relatives and friends, patient advocacy organisations, physicians, scientists, academic organisations, research institutions, hospitals, employees, consultants and other service providers to Mondobiotech.

What is a Rare Disease?

It is estimated that there are more than 7'000 rare diseases in the world. Rare diseases are often chronic, progressive, debilitating, disabling, severe and life-threatening. They disproportionately affect infants and children. Information about them is scarce and the research pipeline inadequate.

People afflicted by rare diseases face multiple challenges: diagnosis delays, misdiagnoses, psychological burdens and a lack of practical support. Many rare disease patients are denied their right to receive the highest attainable standard of health care. About 60 million people in USA and Europe are directly affected by one or several rare diseases.

Rare diseases frequently affect the entire families of individual patients. More than is the case with common diseases, rare diseases require advocacy on the part of family members in order to obtain information about the disease, appropriate referrals, and access to needed services and treatments.

Conclusion

Our objective is to develop the greatest possible number of medicinal product candidates that promise to significantly improve the lives of the greatest possible number of patients affected by rare and neglected diseases. In pursuing this goal, we seek to have a transformative impact upon the lives of millions.

Fabio Cavalli | Vera Cavalli | Patrick Pozzorini | Dorian Bevec | Michael von und zu Liechtenstein